Изучение AZD5305 в качестве монотерапии и в комбинации с противоопухолевыми агентами у пациентов с прогрессирующими солидными злокачественными опухолями (PETRA)
Модульное открытое многоцентровое исследование фазы I/IIa для оценки безопасности, переносимости, фармакокинетики, фармакодинамики и предварительной эффективности возрастающих доз AZD5305 в качестве монотерапии и в комбинации с противоопухолевыми агентами у пациентов с прогрессирующими солидными злокачественными новообразованиями
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Обзор исследования
Статус
Условия
Подробное описание
This study is a Phase I/IIa modular, open-label, multi-center study of AZD5305 administered orally, either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
- Фаза 1
Контакты и местонахождение
Места учебы
-
-
-
Heidelberg, Австралия, 3084
- Research Site
-
Melbourne, Австралия, 3000
- Research Site
-
-
-
-
-
Budapest, Венгрия, 1122
- Research Site
-
Budapest, Венгрия, 1062
- Research Site
-
Budapest, Венгрия, 1082
- Research Site
-
-
-
-
-
Barcelona, Испания, 08035
- Research Site
-
Madrid, Испания, 28041
- Research Site
-
Madrid, Испания, 28040
- Research Site
-
Madrid, Испания, 28050
- Research Site
-
Málaga, Испания, 29010
- Research Site
-
Pozuelo de Alarcón, Испания, 28223
- Research Site
-
Seville, Испания, 41013
- Research Site
-
-
-
-
-
Milan, Италия, 20141
- Research Site
-
Milan, Италия, 20132
- Research Site
-
Modena, Италия, 41125
- Research Site
-
Naples, Италия, 80131
- Research Site
-
Padova, Италия, 35128
- Research Site
-
Roma, Италия, 00168
- Research Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Канада, V5Z 1K1
- Research Site
-
-
Ontario
-
Toronto, Ontario, Канада, M5G 2M9
- Research Site
-
-
Quebec
-
Montreal, Quebec, Канада, H3T 1E2
- Research Site
-
Montreal, Quebec, Канада, H2X 0A9
- Research Site
-
-
-
-
-
Beijing, Китай, 100142
- Research Site
-
Changchun, Китай, 130021
- Research Site
-
Changsha, Китай, 410013
- Research Site
-
Chengdu, Китай, 610041
- Research Site
-
Chongqing, Китай, 400030
- Research Site
-
Guangzhou, Китай, 510060
- Research Site
-
Harbin, Китай, 150081
- Research Site
-
Jining, Китай, 272029
- Research Site
-
Shandong, Китай
- Research Site
-
Shanghai, Китай, 200032
- Research Site
-
Shanghai, Китай, 200025
- Research Site
-
Taiyuan, Китай, 030001
- Research Site
-
Wuhan, Китай, 430079
- Research Site
-
Xi'an, Китай, 710061
- Research Site
-
-
-
-
-
Bydgoszcz, Польша, 85-796
- Research Site
-
Gdansk, Польша, 80-214
- Research Site
-
Gdynia, Польша, 81-519
- Research Site
-
Grzepnica, Польша, 72-003
- Research Site
-
Lodz, Польша, 90-302
- Research Site
-
Torun, Польша, 87-100
- Research Site
-
Warsaw, Польша, 02-781
- Research Site
-
-
-
-
-
Moscow, Россия, 115478
- Research Site
-
Moscow, Россия, 117997
- Research Site
-
Moscow, Россия, 111123
- Research Site
-
Moscow, Россия, 143442
- Research Site
-
-
-
-
-
Cambridge, Соединенное Королевство, CB2 0QQ
- Research Site
-
Manchester, Соединенное Королевство, M20 4BX
- Research Site
-
Oxford, Соединенное Королевство, OX3 7LE
- Research Site
-
Sutton, Соединенное Королевство, SM2 5PT
- Research Site
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02114
- Research Site
-
Boston, Massachusetts, Соединенные Штаты, 02215
- Research Site
-
-
New York
-
New York, New York, Соединенные Штаты, 10021
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Соединенные Штаты, 73104
- Research Site
-
-
Texas
-
Houston, Texas, Соединенные Штаты, 77030
- Research Site
-
-
-
-
-
Chernivtsі, Украина, 58013
- Research Site
-
Ivano-Frankivsk, Украина, 76018
- Research Site
-
Kyiv, Украина, 03022
- Research Site
-
Uzhhorod, Украина, 88000
- Research Site
-
-
-
-
-
Brno, Чехия, 656 53
- Research Site
-
Prague, Чехия, 15006
- Research Site
-
-
-
-
-
Seoul, Южная Корея, 03080
- Research Site
-
Seoul, Южная Корея, 03722
- Research Site
-
Seoul, Южная Корея, 05505
- Research Site
-
Seoul, Южная Корея, 06351
- Research Site
-
-
-
-
-
Chūōku, Япония, 104-0045
- Research Site
-
Kōtoku, Япония, 135-8550
- Research Site
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Key Inclusion Criteria:
- Age ≥ 18 at the time of screening
- Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and meeting module specific eligibility criteria..
- Eastern Cooperative Oncology Group Performance status (ECOG PS: 0-2)
- Life expectancy ≥ 12 weeks
- Progressive cancer at the time of study entry
- Patients must have evaluable disease as defined in module-specific criteria for Part A and Part B
- Adequate organ and marrow function as defined by the protocol.
- For Part B expansion cohorts: Provision of formalin-fixed and paraffin embedded (FFPE) tumour specimen is mandatory, where available, except if stated that it is optional in a specific Module.
For Part A:
- Patients may have received up to one prior line of therapy with a PARPi-based regimen (either as a treatment or as maintenance)
For Part B:
- Patients must not have received prior therapy with a PARPi-based regimen (either as a treatment or as maintenance).
Key Exclusion Criteria:
-
Treatment with any of the following:
- Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment
- Any investigational agents or study drugs from a previous clinical study within 5 half-lives or 3 weeks (whichever is shorter) of the first dose of study treatment
- Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks of the first dose of study treatment
- Any live virus or bacterial vaccine within 28 days of the first dose of study treatment
-
Concomitant use of medications or herbal supplements known to be cytochrome P450 3A4 (CYP3A4) strong inhibitors or inducers.
-
Concomitant use of drugs that are known to prolong or shorten QT and have a known risk of Torsades de Pointes.
-
Receiving continuous corticosteroids at a dose of >10 mg prednisone/day or equivalent for any reason.
-
Major surgery within 4 weeks of the first dose of study treatment.
-
Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study treatment.
-
Any history of persisting (> 2 weeks) severe pancytopenia due to any cause
-
Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of >10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded.
-
patient with known predisposition to bleeding (e.g., active peptic ulceration, recent [within 6 months] haemorrhagic stroke, proliferative diabetic retinopathy).
-
Cardiac conditions as defined by the clinical study protocol
-
Other cardiovascular diseases as defined by any of the following:
- Symptomatic heart failure,
- uncontrolled hypertension,
- hypertensive heart disease with significant left ventricular hypertrophy
- acute coronary syndrome (ACS)/acute myocardial infarction (AMI), unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 6 months.
- cardiomyopathy of any etiology
- presence of clinically significant valvular heart disease
- history of atrial or ventricular arrhythmia requiring treatment; subjects with atrial fibrillation and optimally controlled ventricular rate (< 100 beats per minute) are permitted.
- subjects with atrial fibrillation and optimally controlled ventricular rate are permitted
- transient ischaemic attack, or stroke within 6 months prior to screening
- patients with symptomatic hypotension at screening
-
Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).
-
Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305
-
Known allergy or hypersensitivity to investigational product(s) or any of the excipients of the investigational product(s).
Prior malignancy whose natural history, in the Investigator's opinion, has the potential to interfere with safety and efficacy assessments of the investigational regimen.
other module-specific criteria may apply
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Последовательное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Module 1: AZD5305 Monotherapy
AZD5305 Monotherapy |
Oral PARP inhibitor |
|
Экспериментальный: Module 2: AZD5305 + Paclitaxel
AZD5305 + Paclitaxel |
Oral PARP inhibitor IV Anti-microtubule agent |
|
Экспериментальный: Module 3: AZD5305 + Carboplatin with or without Paclitaxel
AZD5305 + Carboplatin with or without Paclitaxel |
Oral PARP inhibitor IV Anti-microtubule agent IV Platinum chemotherapeutic |
|
Экспериментальный: Module 4: AZD5305 + Trastuzumab Deruxtecan
AZD5305 + T- DXd |
Oral PARP inhibitor IV Antibody-drug conjugate |
|
Экспериментальный: Module 5 AZD5305 + Datopotamab Deruxtecan
AZD5305 + Dato-DXd |
Oral PARP inhibitor IV Antibody-drug conjugate |
|
Экспериментальный: Module 6 AZD5305 + Camizestrant
AZD5305 + Camizestrant |
Oral PARP inhibitor Oral SERD Molecule |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
The number of subjects with adverse events/serious adverse events
Временное ограничение: From time of Informed Consent to 28 + 7 days post last dose ( modules 1,2,3,5 and 6). 40+7 days post last dose for Module 4.
|
Number of patients with adverse events and with serious adverse events including abnormal clinical observations, abnormal ECG parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline |
From time of Informed Consent to 28 + 7 days post last dose ( modules 1,2,3,5 and 6). 40+7 days post last dose for Module 4.
|
|
The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.
Временное ограничение: From first dose of study treatment until the end of Cycle 1.
|
A DLT is defined as any toxicity that occurs from the first dose of study treatment (either AZD5305 or combination anti-cancer agent) up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation. DLTs occurring outside the DLT window (ie, late onset toxicities) may be defined as a DLT after consultation with the sponsor and investigators, based on the emerging safety profile. |
From first dose of study treatment until the end of Cycle 1.
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Best percentage change in target lesion
Временное ограничение: From Screening to confirmed progressive disease (approximately 1 year)
|
Change in target lesion size from baseline, as defined by RECIST 1.1. |
From Screening to confirmed progressive disease (approximately 1 year)
|
|
Objective Response Rate
Временное ограничение: From Screening to confirmed progressive disease (approximately 1 year)
|
Best response until progression, as defined by RECIST 1.1. |
From Screening to confirmed progressive disease (approximately 1 year)
|
|
Duration of Response
Временное ограничение: From Screening to confirmed progressive disease (approximately 1 year)
|
Time from first response to progression or death , as defined by RECIST 1.1. |
From Screening to confirmed progressive disease (approximately 1 year)
|
|
Progression Free Survival
Временное ограничение: From Screening to confirmed progressive disease (approximately 1 year)
|
Time from C1D1 to progression or death, as defined by RECIST 1.1. |
From Screening to confirmed progressive disease (approximately 1 year)
|
|
Time To Response
Временное ограничение: From Screening to confirmed progressive disease (approximately 1 year)
|
Time from C1D1 to complete or partial response, as defined by RECIST 1.1. |
From Screening to confirmed progressive disease (approximately 1 year)
|
|
Effects of AZD5305 on pH2AX (Ser139) PD biomarker
Временное ограничение: From Cycle 0 Day 1 to Cycle 1 Day 15 (approximately 21 days)
|
Measure change from baseline in pH2AX |
From Cycle 0 Day 1 to Cycle 1 Day 15 (approximately 21 days)
|
|
CA125 response (ovarian cancer)
Временное ограничение: From Screening to confirmed progressive disease (approximately 1 year)
|
at least a 50% reduction in CA125 levels from a pre-treatment sample as defined by GCIG criteria. |
From Screening to confirmed progressive disease (approximately 1 year)
|
|
Module 1: Area Under Curve (AUC)
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered. |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
|
Module 1: Maximum plasma concentration of the drug (Cmax)
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
The concentration of AZD5305 in plasma will be determined (Cmax will be derived). |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
|
Module 1: The time taken to reach the maximum concentration (Tmax)
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
The concentration of AZD5305 in plasma will be determined (Tmax will be derived). |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
|
Module 1 and Module 5: Objective Response Rate (prostate cancer)
Временное ограничение: From Screening to confirmed progressive disease (approximately 1 year)
|
Best response until progression, as defined by RECIST 1.1 or PCWG3 (bone) |
From Screening to confirmed progressive disease (approximately 1 year)
|
|
Module 1: Radiographic progression free survival (prostate cancer)
Временное ограничение: From Screening to confirmed progressive disease (approximately 1 year)
|
Time from C1D1 to progression or death, as defined by RECIST 1.1 and PCWG3(bone). |
From Screening to confirmed progressive disease (approximately 1 year)
|
|
Module 1: Proportion of subjects with ≥ 50% PSA decrease (prostate cancer)
Временное ограничение: From Screening to confirmed progressive disease (approximately 1 year)
|
PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment |
From Screening to confirmed progressive disease (approximately 1 year)
|
|
Module 1 : To investigate the effect of a high-fat meal on the PK of AZD5305
Временное ограничение: Cycle 0, Day 1 (C0D1), in either the "fasted" or "fed" state, followed by a single oral dose of AZD5305 in the other state for Cycle 1, Day 1 (C1D1) at least 72 hours later; 1 cycle is 28 days.
|
Effect on High fat meal on PK parameters of AZD5305.PK parameters, including but not limited to AUC and/or AUC(0-t), Cmax, Tmax, AUC(0-t) and Cmax ratio, with and without food |
Cycle 0, Day 1 (C0D1), in either the "fasted" or "fed" state, followed by a single oral dose of AZD5305 in the other state for Cycle 1, Day 1 (C1D1) at least 72 hours later; 1 cycle is 28 days.
|
|
Module 2: Area Under Curve (AUC)
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered. |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
|
Module 2: Maximum plasma concentration of the drug (Cmax)
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
The concentration of AZD5305 in plasma will be determined (Cmax will be derived). |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
|
Module 2: The time taken to reach the maximum concentration (Tmax)
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
The concentration of AZD5305 in plasma will be determined (Tmax will be derived). |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
|
Module 3: Area Under Curve (AUC)
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered. |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
|
Module 3: Maximum plasma concentration of the drug (Cmax)
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
The concentration of AZD5305 in plasma will be determined (Cmax will be derived). |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
|
Module 3: The time taken to reach the maximum concentration (Tmax)
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
The concentration of AZD5305 in plasma will be determined (Tmax will be derived). |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
|
Module 4 : Area Under Curve
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered. |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
|
Module 4: Maximum plasma concentration of the drug (Cmax)
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
The concentration of AZD5305 in plasma will be determined (Cmax will be derived). |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
|
Module 4: The time taken to reach the maximum concentration (Tmax)
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
The concentration of AZD5305 in plasma will be determined (Tmax will be derived). |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
|
Module 4: Anti-Drug Antibody (ADA)
Временное ограничение: Samples will be collected within 1 hour before dose administration on Day 1 of Cycle 1, 2, and 4, then every 4 Cycles (each cycle is 21 days), EoT, and at safety follow-up (40 days after last dose) as per Schedule of Assessments
|
To investigate the presence of ADAs for T-DXd |
Samples will be collected within 1 hour before dose administration on Day 1 of Cycle 1, 2, and 4, then every 4 Cycles (each cycle is 21 days), EoT, and at safety follow-up (40 days after last dose) as per Schedule of Assessments
|
|
Module 4: To assess the preliminary anti-tumour activity of AZD5305 as monotherapy and in combination with T-DXd.
Временное ограничение: From screening to approximately 6 months
|
Time from C1D1 to progression or death, as defined by RECIST v 1.1 summarised at the 6 month landmark (PFS6) |
From screening to approximately 6 months
|
|
Module 5: Area Under Curve
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered. |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
|
Module 5: Maximum plasma concentration of the drug (Cmax)
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
The concentration of AZD5305 in plasma will be determined (Cmax will be derived). |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
|
Module 5: The time taken to reach the maximum concentration (Tmax)
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
The concentration of AZD5305 in plasma will be determined (Tmax will be derived). |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
|
Module 5: Anti-Drug Antibody (ADA)
Временное ограничение: Whole blood samples for determination of ADA for Dato-DXd in plasma will be collected in patients receiving Dato-DXd per the schedule specified in the SoA : Day 1 of Cycle 1, 2, 4, and 8 (each cycle is 21 days) , EoT, and then 28 day follow up visit.
|
Presence of ADAs for Dato-DXd |
Whole blood samples for determination of ADA for Dato-DXd in plasma will be collected in patients receiving Dato-DXd per the schedule specified in the SoA : Day 1 of Cycle 1, 2, 4, and 8 (each cycle is 21 days) , EoT, and then 28 day follow up visit.
|
|
Module 5: Premilinary anti tumour activity AZD5305 in combination with Dato-DXd
Временное ограничение: From screening to confirmed progresive disease ( approximately 12 weeks)
|
objective response rate and radiographic progression-free survival using RECIST v1.1. Proportion of patients achieving a ≥ 50% decrease in PSA from baseline to the post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later (PSA50 response). |
From screening to confirmed progresive disease ( approximately 12 weeks)
|
|
Module 6: To characterise the PK of AZD5305 and camizestrant following a single dose and at steady state after multiple dosing, when given in combination.
Временное ограничение: At predefined interval throughout the treatment (approximately 12 weeks)
|
Plasma concentrations and PK parameters of AZD5305 and camizestrant after single dose and multiple dose administration, including, but not limited to: AUC, Cmax, Tmax, as data allow |
At predefined interval throughout the treatment (approximately 12 weeks)
|
|
Module 6: To evaluate the effect of camizestrant on the PK of AZD5305.
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
PK parameters, including but not limited to AUC and/or AUC(0-t), Cmax, Tmax, AUC(0-t) and Cmax ratio, with and without camizestrant. |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
|
Module 6: To evaluate the effect of AZD5305 on the PK of Camizestrant.
Временное ограничение: At predefined intervals throughout the treatment period (approximately 12 weeks)
|
PK parameters, including but not limited to AUC and/or AUC(0-t), Cmax, Tmax, AUC(0-t) and Cmax ratio, with and without AZD5305. |
At predefined intervals throughout the treatment period (approximately 12 weeks)
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Timothy Yap, M.D. Anderson Cancer Center
Публикации и полезные ссылки
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Урогенитальные заболевания
- Генитальные заболевания
- Заболевания эндокринной системы
- Генитальные новообразования, мужчины
- Урогенитальные новообразования
- Новообразования по локализации
- Новообразования
- Заболевания половых органов, мужчины
- Заболевания предстательной железы
- Мужские мочеполовые заболевания
- Урологические заболевания
- Женские урогенитальные заболевания
- Женские мочеполовые заболевания и осложнения беременности
- Кишечные заболевания
- Заболевания дыхательных путей
- Желудочно-кишечные новообразования
- Новообразования пищеварительной системы
- Заболевания пищеварительной системы
- Желудочно-кишечные заболевания
- Заболевания желудка
- Новообразования кишечника
- Заболевания прямой кишки
- Заболевания матки
- Заболевания половых органов, Женский
- Легочные заболевания
- Новообразования эндокринных желез
- Заболевания поджелудочной железы
- Заболевания желчевыводящих путей
- Новообразования дыхательных путей
- Грудные новообразования
- Заболевания толстой кишки
- Новообразования легких
- Заболевания яичников
- Заболевания придатков
- Генитальные Новообразования, Женщины
- Заболевания гонад
- Кожные заболевания
- Заболевания груди
- Урологические новообразования
- Заболевания шейки матки
- Рак, Бронхогенный
- Бронхиальные новообразования
- Новообразования матки
- Заболевания мочевого пузыря
- Заболевания кожи и соединительной ткани
- Новообразования предстательной железы
- Новообразования желудка
- Новообразования желчевыводящих путей
- Колоректальные новообразования
- Новообразования яичников
- Новообразования молочной железы
- Новообразования поджелудочной железы
- Карцинома немелкоклеточного легкого
- Новообразования шейки матки
- Новообразования мочевого пузыря
- Новообразования эндометрия
- Органические химические вещества
- Углеводороды
- Циклопарафины
- Углеводороды, алициклический
- Углеводороды, циклические
- Терпена
- Координационные комплексы
- Таксииды
- Циклодеканы
- Diterpenes
- Карбоплатин
- Паклитаксел
- AZD5305
- AZD9833
Другие идентификационные номера исследования
- D9720C00001
- 2020-002688-77 (Номер EudraCT)
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .